Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors
Main Article Content
Keywords
cemiplimab
References
2. Mohan SV et al. Curr Dermatol Rep. 2014;3:40–45.
3. Sun Pharma Global FZE. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205266s004lbl.pdf. Accessed June 10, 2021.
4. Roche. Available from: https://www.gene.com/download/pdf/erivedge_prescribing.pdf. Accessed June 10, 2021.
5. Burova E et al. Mol Cancer Ther. 2017;16:861–870.
6. Stratigos AJ et al. Lancet Oncol. 2021;22:848–857.
7. Regeneron Pharmaceuticals, Inc. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf. Accessed January 28, 2022.
8. European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo. Accessed December 3, 2021.
9. Sanofi-aventis Canada, Inc. Available from: https://pdf.hres.ca/dpd_pm/00063482.PDF. Accessed February 23, 2022.
10. Health Canada. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/
libtayo-notice-compliance-conditions-218718.html. Accessed January 28, 2022.
11. Brazilian Health Authority - ANVISA. Available from: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/libtayocemiplimabe-
nova-indicacao. Accessed January 28, 2022.
12. Eisenhauer EA et al. Eur J Cancer. 2009;45:228–247.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.